Parenteral and Inhaled Colistin for Treatment of Ventilator-Associated Pneumonia
Open Access
- 1 September 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (Supplement), S89-S94
- https://doi.org/10.1086/504485
Abstract
The spectrum of available therapeutic options has become drastically narrowed in recent years, particularly for nosocomial multidrug-resistant gram-negative pathogens. This therapeutic void has created a resurgence of interest in colistin. In 5 published series since 1999, clinical response rates for pneumonia due to Pseudomonas aeruginosa or Acinetobacter baumannii treated with intravenous colistin have ranged from 25% to 62%, despite high severity of illness at baseline. De novo nephrotoxicity was observed in 8%-36% of patients, despite close attention to both appropriate dosing and duration of treatment. Neurotoxicity, which was commonly described in the old colistin era, has been exceedingly rare in recent experience. Aerosolized therapy as an adjunct to systemic treatment appears promising, but the current published data are much too limited to allow determination of the incremental benefit of the addition of aerosolized treatment to systemic treatment. Colistin is a reasonably safe last-line therapeutic alternative for pneumonia due to multi- or panresistant P. aeruginosa or A. baumannii.Keywords
This publication has 39 references indexed in Scilit:
- Combination Therapy with Intravenous Colistin for Management of Infections Due to Multidrug-Resistant Gram-Negative Bacteria in Patients without Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2005
- Use of Parenteral Colistin for the Treatment of Serious Infection Due to Antimicrobial-Resistant Pseudomonas aeruginosaClinical Infectious Diseases, 2003
- Treatment of Multidrug‐ResistantAcinetobacter baumanniiVentilator‐Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem‐Susceptible VAPClinical Infectious Diseases, 2003
- Transmission of colistin‐resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis centerPediatric Pulmonology, 2002
- Short report: Bronchoconstriction following nebulised colistin in cystic fibrosisArchives of Disease in Childhood, 2001
- Epidemiology and Clinical Outcomes of Patients with Multiresistant Pseudomonas aeruginosaClinical Infectious Diseases, 1999
- Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumanniiClinical Infectious Diseases, 1999
- Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infectionJournal of Antimicrobial Chemotherapy, 1987
- TETRACYCLINE-SENSITIVE/POLYMYXIN-RESISTANT PSEUDOMONAS ÆRUGINOSAThe Lancet, 1972
- Effects of Large Doses of Colistin Sulphomethate Sodium on Renal FunctionBMJ, 1970